Zura Bio (ZURA) Q2 2026 earnings summary

Executive summary

• Completed enrollment for two Phase 2 tibulizumab studies (TibuSHIELD in HS and TibuSURE in SSc), both exceeding initial targets; topline results expected in Q4 2026 and H1 2027.

• Announced plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026, following supportive FDA feedback.

• Raised $134.6 million in net proceeds from a February 2026 equity offering to support ongoing R&D and operations.

• Cash and cash equivalents of $205.1 million as of June 30, 2026, expected to fund operations through at least end of 2028.

Financial highlights

• Cash and cash equivalents totaled $205.1 million as of June 30, 2026.

• Net loss was $26.3 million for Q2 2026 and $50.5 million for the six months ended June 30, 2026, compared to $16.0 million and $33.4 million for the same periods in 2025.

• Research and development expenses increased 138% year-over-year to $20.7 million for Q2 2026, driven by clinical trial and manufacturing costs.

• General and administrative expenses were $8.6 million for Q2 2026, down 8% year-over-year.

• Weighted-average shares outstanding increased to 126.8 million for Q2 2026.

Outlook and guidance

• Sufficient liquidity to fund operations through at least the end of 2028 based on current business plans.

• Topline data for TibuSHIELD expected in Q4 2026; TibuSURE topline data expected in H1 2027.

• Phase 2 study for tibulizumab in PMR planned to start by year-end 2026.

• Anticipates continued increase in R&D expenses as clinical programs advance and new studies are initiated.

• No revenue expected from product sales in the near term; ongoing reliance on external financing.